Applied DNA Sciences to Present 'The Power of DNA in Detecting and Defeating Pharmaceutical Counterfeiting' at the Anti-Counterfeiting for Pharmaceuticals Conference

Jan 29, 2007, 00:00 ET from Applied DNA Sciences, Inc.

    STONY BROOK, N.Y., Jan. 29 /PRNewswire-FirstCall/ -- Applied DNA
 Sciences, Inc. (OTC Bulletin Board:   APDN), a DNA security solutions
 company, today announced that Dr. James A. Hayward, Chief Executive
 Officer, will deliver a presentation at the Anti-Counterfeiting for
 Pharmaceuticals Conference to be held January 30-31 in Philadelphia, PA.
     The counterfeiting of pharmaceuticals is a large and growing problem
 throughout the world. It has been estimated that the pharmaceutical
 industry loses $32 billion to counterfeiting globally each year (U.S.
 Chamber of Commerce). A study by Columbia University's National Center on
 Addiction and Substance Abuse documented that only 11% of internet
 pharmacies are legitimate. In 2006, the Center for Medicine in the Public
 Interest predicted that counterfeit drug sales would increase more than 90%
 from 2005 levels to reach $75 billion globally by 2010, nearly twice the
 growth rate of legitimate pharmaceuticals. According to the World Health
 Organization, over 10% of the global medicine market is estimated to be
 counterfeit, posing a health threat to patients everywhere.
     Dr. Hayward's talk, entitled "The Power of DNA in Detecting and
 Defeating Pharmaceutical Counterfeiting," will address this disturbing
 trend and present the use of DNA embedment to combat counterfeiting in
 pharmaceuticals. DNA embedment offers a broadly applicable, convenient and
 inexpensive way to help protect pharmaceuticals from counterfeiting. APDN's
 platform for DNA embedment, uses unique DNA "chimers," is derived from
 botanical sources, and is marketed as the "SigNature" brand. The SigNature
 DNA Markers are highly resistant to reverse engineering or replication, and
 can either be applied independently or to supplement other security
 taggants in order to allow for a forensic level of authentication. APDN's
 SigNature DNA Markers can easily be embedded directly into pharmaceutical
 packaging, combined with RFID (radio frequency identification) tags,
 holograms, or EPC's (electronic product codes). APDN has demonstrated that
 our SigNature DNA markers may be applied directly onto single unit doses of
 drugs such as pressed tablets, and thereby ensure drug authenticity
 regardless of packaging.
     "This is a rapidly growing problem which threatens the health and
 safety of people everywhere." Dr. Hayward stated. "APDN's SigNature Program
 can quickly and reliably authenticate and identify counterfeit versions of
 pharmaceuticals, diminishing product diversion and enabling companies to
 detect, deter, interdict and prosecute counterfeiting enterprises and
 individuals. I welcome this opportunity to introduce the potential power of
 our DNA technology as both a way to deter counterfeiting and help protect
     About Applied DNA Sciences, Inc.
     Applied DNA Sciences, Inc. (APDN) provides botanical DNA encryption,
 embedment and authentication solutions that can help protect companies,
 governments and consumers from counterfeiting, fraud, piracy, product
 diversion, identity theft and unauthorized intrusion into physical
 locations and databases. Our common stock is registered under Section 12(g)
 of the Securities Exchange Act of 1934 and is listed on the
 Over-The-Counter Bulletin Board under the symbol "APDN". Contact: Debbie
 Bailey, Applied DNA Sciences, Inc., 25 Health Sciences Drive, Stony Brook,
 New York 11790; Tel: 631-444- 8090; Fax: 631-444-8848
     The statements made by Applied DNA Sciences, Inc. may be
 forward-looking in nature and are made pursuant to the safe harbor
 provisions of the Private Securities Litigation Reform Act of 1995.
 Forward-looking statements describe the Company's future plans,
 projections, strategies and expectations, and are based on assumptions and
 involve a number of risks and uncertainties, many of which are beyond the
 control of Applied DNA Sciences, Inc. Actual results could differ
 materially from those projected due to our short operating history, limited
 market acceptance, market competition and various other factors detailed
 from time to time in Applied DNA Sciences' SEC reports and filings,
 including our Registration Statement on Form SB-2 as amended, and our
 Annual Report on Form 10-KSB, filed on January 16, 2007. The Company
 undertakes no obligation to update publicly any forward-looking statements
 to reflect new information, events or circumstances after the date hereof
 to reflect the occurrence of unanticipated events.

SOURCE Applied DNA Sciences, Inc.